| Welcome
to the 14th issue of PharmaView!
Pharmaceutical Marketers
are facing increasing pressures: increasing competition; squeezed
margins; shrinking budgets; more to do and less time to do it. It’s
becoming difficult to work any harder, and of course it's always
better to work smarter. Therefore we bring you the PharmaView.
PharmaView is a biweekly
educational and informative newsletter for improving readers’
marketing knowledge and reporting the latest news in the pharma
industry. It also provides great opportunities to exchange ideas,
network and be recognized among your peers in the
industry.
Through PharmaView, you can:
Learn peer’s experience
in pharma marketing
Stay in touch with what’s
happening in pharmaceutical marketing today
Be on the pioneering edge
of pharmaceutical marketing
Have networking / idea
exchange opportunities
 About
Us
Integrating local knowledge with international
perspective, Consultech Co. Ltd. offers its clients and
prospects one-lstop solutions with sales and marketing consultancy,
advertising and promotion strategies.
Consultech is an
affiliate company of Omnicom, the world's largest advertising and
communications holding company
Creative
Design: Case study of
Vytorin Visuals
FDA Approves New Dose of Risperdal Consta for Schizophrenia
Treatment
The U.S. Food and Drug Administration (FDA) approved a 12.5 mg dose
of RISPERDAL(R) CONSTA(R) [(risperidone) Long-Acting Injection] for
the treatment of schizophrenia within specific patient populations,
including those with renal and hepatic impairment.
Apr. 13, 2007
GSK Announces FDA Approval of Altabax (Retapamulin Ointment), 1%
GlaxoSmithKline announced today that the U.S. Food and Drug
Administration (FDA) has approved its antibacterial Altabax for the
topical treatment of impetigo due to susceptible strains of
Staphylococcus aureus or Streptococcus pyogenes, the two most common
types of bacteria in this kind of infection.
Apr. 12, 2007
Abbott Announces FDA Approval of a New Coated Niaspan Tablet
The U.S. Food and Drug Administration (FDA) has approved Abbott's
new coated Niaspan(R) (niacin extended-release tablets). Niaspan is
the leading medication for boosting HDL cholesterol -- the "good"
cholesterol.
Apr. 06, 2007
Pharmaceutical marketing: just what the doctor ordered?
Clear, accurate and comprehensive information should be readily and
easy available. But is DTC advertising the best remedy?
Apr. 06, 2007
Pharma companies have been blasting out electronic newsletters to
consumers since the advent of new media. But far too often, the
content is vague and redundant, and instead of striking a responsive
chord with potential readers, e-lmail campaigns are more likely to
prompt a strike of the delete key.
Syndax Pharmaceuticals, Inc. Licenses Selective Histone Deacetylase
Inhibitor MS-275
Syndax Pharmaceuticals, Inc. announced today that it has entered
into an exclusive licensing agreement with Bayer Schering Pharma AG
for the acquisition of worldwide rights to the selective histone
deacetylase inhibitor (HDACi) MS-275, which becomes known as
SNDX-275. Under the terms of the agreement, Syndax will develop and
commercialize the compound, while Bayer Schering Pharma will receive
upfront and milestone payments.
Apr 13, 2007
FDA May OK Arcoxia, a Vioxx Follow-Up
Merck & Co. Inc. shares showed little reaction Tuesday to the
release of government documents reviewing the pain-relieving drug
Arcoxia.
Apr. 10, 2007
Renovis, Pfizer Extend Research Pact
Biotech drug developer Renovis Inc. said Tuesday
it extended its research agreement with Pfizer Inc. until
2008 for a class of compounds that affect cell signaling.
Apr. 10, 2007
Please feel free to offer your opinions and advices about
PharmaView in order to better our services. Should you have any
comments, or if you want to unsubscribe from PharmaView,
please send us an email:
pharmaview@Consultech.com.cn . Thank
you!
| 
